对服用抗酸剂的晚期非小细胞肺癌患者使用免疫检查点抑制剂的分析

IF 2.4 Q2 RESPIRATORY SYSTEM Respiratory investigation Pub Date : 2024-08-25 DOI:10.1016/j.resinv.2024.08.013
Taisuke Isono, Hajime Furuno, Yoko Onodera, Tomoya Maruyama, Yuki Takeuchi, Ayaka Kojima, Takashi Nishida, Yoichi Kobayashi, Takashi Ishiguro, Yotaro Takaku, Kazuyoshi Kurashima, Naho Kagiyama
{"title":"对服用抗酸剂的晚期非小细胞肺癌患者使用免疫检查点抑制剂的分析","authors":"Taisuke Isono,&nbsp;Hajime Furuno,&nbsp;Yoko Onodera,&nbsp;Tomoya Maruyama,&nbsp;Yuki Takeuchi,&nbsp;Ayaka Kojima,&nbsp;Takashi Nishida,&nbsp;Yoichi Kobayashi,&nbsp;Takashi Ishiguro,&nbsp;Yotaro Takaku,&nbsp;Kazuyoshi Kurashima,&nbsp;Naho Kagiyama","doi":"10.1016/j.resinv.2024.08.013","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Proton pump inhibitors (PPIs) are reported to decrease the efficacy of immune checkpoint inhibitors (ICIs), but there are few reports on the association between ICI efficacy and antacids other than PPIs, and simultaneous examination of the effects of antacids, corticosteroids, and non-steroidal anti-inflammatory drugs (NSAIDs) on ICI therapy.</p></div><div><h3>Methods</h3><p>We conducted a retrospective study of 381 patients with non-small cell lung cancer who received ICI therapy from January 1, 2016 to December 31, 2022. The primary endpoint was overall survival (OS) and the secondary endpoint was progression-free survival (PFS). Antacids included histamine type 2 receptor antagonists (H2RAs), PPIs, and potassium-competitive acid blockers (P-CABs).</p></div><div><h3>Results</h3><p>Antacids were administered to 218 patients, including 168 with PPIs, 37 with P-CABs, and 13 with H2RAs. Patients with antacids had worse median PFS and OS than those without antacids (PFS, 2.9 vs. 6.2 months; OS, 12.3 vs. 24.0 months), and those with PPIs, P-CABs, or H2RAs had similar results. However, there were no significant differences between patients with and without antacids when stratified by corticosteroid and NSAID use. Multivariate analyses showed that corticosteroids and NSAIDs administered for cancer-associated symptoms were related to poor prognosis, but antacids including PPIs, P-CABs, or H2RAs were not related.</p></div><div><h3>Conclusions</h3><p>Antacids were not related to ICI efficacy when NSAIDs or corticosteroids were taken into consideration. This may be because the most frequent reason for administering NSAIDs and corticosteroids was cancer-associated symptoms, which are a poor prognostic factor, and most of the patients treated with these medications also received antacids.</p></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"62 6","pages":"Pages 951-959"},"PeriodicalIF":2.4000,"publicationDate":"2024-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Analysis of immune checkpoint inhibitors for advanced non-small cell lung cancer in patients receiving antacids\",\"authors\":\"Taisuke Isono,&nbsp;Hajime Furuno,&nbsp;Yoko Onodera,&nbsp;Tomoya Maruyama,&nbsp;Yuki Takeuchi,&nbsp;Ayaka Kojima,&nbsp;Takashi Nishida,&nbsp;Yoichi Kobayashi,&nbsp;Takashi Ishiguro,&nbsp;Yotaro Takaku,&nbsp;Kazuyoshi Kurashima,&nbsp;Naho Kagiyama\",\"doi\":\"10.1016/j.resinv.2024.08.013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Proton pump inhibitors (PPIs) are reported to decrease the efficacy of immune checkpoint inhibitors (ICIs), but there are few reports on the association between ICI efficacy and antacids other than PPIs, and simultaneous examination of the effects of antacids, corticosteroids, and non-steroidal anti-inflammatory drugs (NSAIDs) on ICI therapy.</p></div><div><h3>Methods</h3><p>We conducted a retrospective study of 381 patients with non-small cell lung cancer who received ICI therapy from January 1, 2016 to December 31, 2022. The primary endpoint was overall survival (OS) and the secondary endpoint was progression-free survival (PFS). Antacids included histamine type 2 receptor antagonists (H2RAs), PPIs, and potassium-competitive acid blockers (P-CABs).</p></div><div><h3>Results</h3><p>Antacids were administered to 218 patients, including 168 with PPIs, 37 with P-CABs, and 13 with H2RAs. Patients with antacids had worse median PFS and OS than those without antacids (PFS, 2.9 vs. 6.2 months; OS, 12.3 vs. 24.0 months), and those with PPIs, P-CABs, or H2RAs had similar results. However, there were no significant differences between patients with and without antacids when stratified by corticosteroid and NSAID use. Multivariate analyses showed that corticosteroids and NSAIDs administered for cancer-associated symptoms were related to poor prognosis, but antacids including PPIs, P-CABs, or H2RAs were not related.</p></div><div><h3>Conclusions</h3><p>Antacids were not related to ICI efficacy when NSAIDs or corticosteroids were taken into consideration. This may be because the most frequent reason for administering NSAIDs and corticosteroids was cancer-associated symptoms, which are a poor prognostic factor, and most of the patients treated with these medications also received antacids.</p></div>\",\"PeriodicalId\":20934,\"journal\":{\"name\":\"Respiratory investigation\",\"volume\":\"62 6\",\"pages\":\"Pages 951-959\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-08-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Respiratory investigation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2212534524001345\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory investigation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212534524001345","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

摘要

背景据报道,质子泵抑制剂(PPIs)会降低免疫检查点抑制剂(ICIs)的疗效,但关于ICI疗效与PPIs以外的抗酸剂之间的关联,以及同时检查抗酸剂、皮质类固醇和非甾体抗炎药(NSAIDs)对ICI治疗的影响的报道却很少。主要终点是总生存期(OS),次要终点是无进展生存期(PFS)。抗酸药包括组胺2型受体拮抗剂(H2RAs)、PPIs和钾竞争性酸阻滞剂(P-CABs)。结果 218例患者服用了抗酸药,其中168例服用了PPIs,37例服用了P-CABs,13例服用了H2RAs。与未服用抗酸药的患者相比,服用抗酸药患者的中位 PFS 和 OS 更差(PFS,2.9 个月 vs. 6.2 个月;OS,12.3 个月 vs. 24.0 个月),而服用 PPI、P-CAB 或 H2RA 的患者结果相似。然而,根据皮质类固醇和非甾体抗炎药的使用情况进行分层后,使用和未使用抗酸药的患者之间没有明显差异。多变量分析表明,因癌症相关症状而使用皮质类固醇和非甾体抗炎药与预后不良有关,但抗酸药(包括 PPI、P-CAB 或 H2RA)与预后不良无关。这可能是因为使用非甾体抗炎药和皮质类固醇的最常见原因是癌症相关症状,而这是一个不良预后因素,而且大多数使用这些药物治疗的患者也服用了抗酸剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Analysis of immune checkpoint inhibitors for advanced non-small cell lung cancer in patients receiving antacids

Background

Proton pump inhibitors (PPIs) are reported to decrease the efficacy of immune checkpoint inhibitors (ICIs), but there are few reports on the association between ICI efficacy and antacids other than PPIs, and simultaneous examination of the effects of antacids, corticosteroids, and non-steroidal anti-inflammatory drugs (NSAIDs) on ICI therapy.

Methods

We conducted a retrospective study of 381 patients with non-small cell lung cancer who received ICI therapy from January 1, 2016 to December 31, 2022. The primary endpoint was overall survival (OS) and the secondary endpoint was progression-free survival (PFS). Antacids included histamine type 2 receptor antagonists (H2RAs), PPIs, and potassium-competitive acid blockers (P-CABs).

Results

Antacids were administered to 218 patients, including 168 with PPIs, 37 with P-CABs, and 13 with H2RAs. Patients with antacids had worse median PFS and OS than those without antacids (PFS, 2.9 vs. 6.2 months; OS, 12.3 vs. 24.0 months), and those with PPIs, P-CABs, or H2RAs had similar results. However, there were no significant differences between patients with and without antacids when stratified by corticosteroid and NSAID use. Multivariate analyses showed that corticosteroids and NSAIDs administered for cancer-associated symptoms were related to poor prognosis, but antacids including PPIs, P-CABs, or H2RAs were not related.

Conclusions

Antacids were not related to ICI efficacy when NSAIDs or corticosteroids were taken into consideration. This may be because the most frequent reason for administering NSAIDs and corticosteroids was cancer-associated symptoms, which are a poor prognostic factor, and most of the patients treated with these medications also received antacids.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Respiratory investigation
Respiratory investigation RESPIRATORY SYSTEM-
CiteScore
4.90
自引率
6.50%
发文量
114
审稿时长
64 days
期刊最新文献
Persistent COVID-19 improved with immunoglobulin replacement therapy in Good's syndrome Clinical characteristics and prognostic factors for MPO-ANCA positive interstitial lung disease: A comparative study of ANCA associated vasculitis (AAV)-ILD and pulmonary limited vasculitis Association of constipation with the survival of patients with idiopathic interstitial pneumonias A protocol for a Japanese prospective cohort evaluating the features of patients with uncontrolled asthma achieving clinical remission: J-CIRCLE Viability and diagnostic potential of tissues obtained through cryobiopsy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1